Development asset linked to Cognition Therapeutics in public FDA and regional records.
biotech · Alzheimer Disease · Major Depressive Disorder · CGTX
Cognition Therapeutics
COGNITION THERAPEUTICS INC
Cognition Therapeutics drug portfolio — 26 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
2500 Westchester Ave, Purchase, New York 10577, US HQ
2007 Founded
32 Employees
Public company Type
CGTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2500 Westchester Ave, Purchase, New York 10577, US
- Founded
- 2007
- Employees
- 32
- Programs
- 33
- Drugs
- 26
- Patents
- 12
Cognition Therapeutics pipeline
Portfolio lens on 26 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Cognition Therapeutics drug portfolio — 26 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Cognition Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
Development asset linked to Cognition Therapeutics in public FDA and regional records.
-
Development asset linked to Cognition Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Cognition Therapeutics in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
dexmedetomidine
Nervous system (N05)Nervous system (N05) compound in Cognition Therapeutics's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to Cognition Therapeutics in public FDA and regional records.
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Oxytocin receptor.
- Target
- Oxytocin receptor
- Mechanism
- Oxytocin receptor agonist
-
Development asset linked to Cognition Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Cognition Therapeutics in public FDA and regional records.
-
Development asset linked to Cognition Therapeutics in public FDA and regional records.
-
Development asset linked to Cognition Therapeutics in public FDA and regional records.
-
Development asset linked to Cognition Therapeutics in public FDA and regional records.
-
tobramycin
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: 70S ribosome.
- Target
- 70S ribosome
- Mechanism
- 70S ribosome inhibitor
-
Development asset linked to Cognition Therapeutics in public FDA and regional records.
-
vortioxetine
Nervous system (N06)US regulatory status: approved. Mechanism: Serotonin 3a (5-HT3a) receptor antagonist.
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist